dual glp 1 and gip receptor agonist The Sustained Effects of a GIP/GLP-1 Agonist, NNC0090-2746, in Patients with Type 2 Diabetes: Cell Metabolism Dual GIP/GLP-1 receptor agonists: New

Description

BCBS may cover Wegovy, but coverage varies by plan, and some dont cover weight loss medications

Researchers are examining whether drugs currently approved to treat obesity and type 2 diabetes could be useful for a wider range of health challenges.

GLP-1 drugs could rapidly evolve beyond current use as diabetes and weight loss medications, with new research pointing to potential benefits in cancer, ageing, addiction, osteoarthritis and heart health

GLP-1/GIP Therapy Discontinuation: Why the How Matters One of the most-discussed challenges with GLP-1/GIP agonists such as tirzepatide (Mounjaro) is weight regain after stopping therapy